Wednesday, August 29, 2018 Daily Archives

Bioproduction Efficiencies Gained Using the New ExpiCHO Stable Production Medium

This webcast features: Shreya Lowmaster, Msc Transition from the transient to stable production workflow exclusively in CHO cells with the new Gibco™ ExpiCHO™ Stable Production Medium and cGMP banked Gibco™ ExpiCHO-S™ cells. Transient titers in shake flasks and stable clone titers in a 50L Thermo Scientific™ HyPerforma™ single-use bioreactor were greater than 3.0 g/L in a fed-batch process with comparable product quality. Just fill out the form to watch the recorded webcast now.

Accelerated Development, Manufacturing and Monitoring of Viral Vectors

The goals of process intensification are to enhance production while shortening timelines, lessening contamination and environmental risks to products and operators, and reducing operating footprints. Previous publications from Sartorius Stedim Biotech (SSB) have highlighted key elements of such activities. In this report, the authors extend the scope of this discussion to tools and technologies that enable intensification of viral vector manufacturing processes. The first article summarizes presentations from a 2018 seminar for viral vaccine manufacturers. Three guest presentations highlighted the…

AGC Bio adding 12,000L of ‘competitive and flexible’ capacity in Denmark

The CDMO will add six 2,000 L single-use bioreactors in Copenhagen and says such a configuration can be competitive compared with an equivalent scale stainless-steel run. A single-use bioreactor 6Pack suite, consisting of six 2,000 L bioreactors and a 2000 L seed train, is to be installed at AGC Biologics’ biomanufacturing plant in Copenhagen, Denmark. According to AGC’s chief business officer Robert Broeze, the ‘6pak’ set-up – consisting of the six bioreactors configurated to run consecutively to produce a total…

Samsung BioLogics says biosimilars important to utilize growing capacity

Samsung BioLogics has begun making biosimilar versions of Enbrel and Remicade for its joint venture Samsung Bioepis, the Korean press reports. South Korean news portal BusinessKorea reported recently that contract development and manufacturing organization (CDMO) Samsung BioLogics has begun pilot production of two products on behalf of customer and joint venture entity Samsung Bioepis. The project sees the firm produce small scale amounts of Benapali and Flixabi, versions of Amgen’s Enbrel (etanercept) and J&J’s Remicade (infliximab) both approved across numerous…